跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 40,263 条关于
“MAPK pathway-driven tumors”
全部
40,263
临床试验
24,812
药物
1,253
机构
128
资讯
14,070
去年
Immuneering Partners with Lilly for Phase 2 NSCLC Combination Trial Testing Dual MAPK Pathway Blockade
9个月前
Pasithea Therapeutics Secures $60 Million Funding to Advance MEK Inhibitor for Neurofibromatosis Treatment
去年
PAS-004 Shows Favorable Safety and Early Efficacy in MAPK-Driven Solid Tumors
去年
Pasithea Therapeutics Raises $6.3 Million to Advance MEK Inhibitor for Neurofibromatosis Type 1
2年前
Pasithea Therapeutics Initiates Phase 1 Trial of PAS-004, a Novel MEK Inhibitor, for Advanced Solid Tumors and NF1
去年
Pasithea's PAS-004 Outperforms FDA-Approved MEK Inhibitor in Preclinical IBD Study
9个月前
Pasithea Therapeutics Receives $1 Million ALS Association Grant to Advance PAS-004 MEK Inhibitor in Phase 1 ALS Trial
9个月前
Immuneering Receives FDA and EMA Alignment for Phase 3 Atebimetinib Trial in First-Line Pancreatic Cancer
2年前
Pasithea Therapeutics Announces FDA Acceptance of IND Application for PAS-004 in Advanced Cancer Patients
去年
Pasithea Therapeutics Expands PAS-004 Clinical Trial to Europe, Completes Dosing in Cohort 4A
第 1 页，共 1407 页
上一页
下一页
